Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with neoadjuvant chemotherapy for PD-L1/CXCL13/TLS-positive ovarian cancer
ChiCTR2400093586Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoints: progression-free survival and objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400093586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093586.